Ivlv-X1 / SZGIMI - LARVOL DELTA

SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection (clinicaltrials.gov) - P1/2 | N=10 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Unknown status ➔ Recruiting | Trial completion date: Dec 2020 ➔ Dec 2027 | Trial primary completion date: Dec 2019 ➔ Dec 2026

Enrollment open • Gene therapy • Trial completion date • Trial primary completion date • Viral vector • Gene Therapies • Genetic Disorders • Immunology • Primary Immunodeficiency